Document is current
Any future updates will be listed below
-
Authors
Otani, Junji https://orcid.org/0009-0009-1239-0636
Nishio, Miki
Tokita, Riko
Hikasa, Hiroki
Nishimori, Makoto
Dan, Shingo https://orcid.org/0000-0002-0022-2725
Naguro, Isao
Ichijo, Hidenori https://orcid.org/0000-0002-5005-6438
Miyanishi, Masanori
Sasaki, Takehiko https://orcid.org/0000-0003-1837-3748
Nishina, Hiroshi https://orcid.org/0000-0002-6647-7480
Mak, Tak Wah
Maehama, Tomohiko https://orcid.org/0000-0002-9685-2317
Suzuki, Akira https://orcid.org/0000-0002-5950-8808
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (25K02518)
MEXT | Japan Society for the Promotion of Science (21H04806)
MEXT | Japan Society for the Promotion of Science (23K06400)
Japan Agency for Medical Research and Development (23ama221117h0002)
Japan Agency for Medical Research and Development (24gm1710007s0102)
Center for Medical Transformation, Kobe University
Mochida Memorial Foundation for Medical and Pharmaceutical Research
Suzuken Memorial Foundation
- License Information
-
More Information
Article History
Received: 9 October 2025
Revised: 6 March 2026
Accepted: 30 March 2026
First Online: 21 April 2026
Competing interests
: The authors declare that they have no competing financial interests concerning the work described in this manuscript. TWM owns equity in Treadwell Therapeutics and Agios Pharmaceuticals, and is a consultant for AstraZeneca and Tessa Therapeutics.
